Investor Presentaiton

Current State of the Market ■ Near-term normalization in the overall demand trends and market dynamics Recent shift in client spending towards commercializing their late-stage clinical programs ■ Biotech funding has slowed from peak 2020-21 levels, but recent signs of stabilization and ample funding available for promising drug candidates ◉ - IPOs and new biotech creation have slowed, but VCs still have capital to deploy and are doing so more selectively - Expect funding to return to more sustainable, pre-pandemic levels based on YTD 2023 activity Big pharma continues to steadily invest in R&D CRL global biopharma revenue growth has exceeded SMID biotech for last 2 quarters Believe pharma will continue to rely on biotech licensing, partnering, and M&A to advance their pipelines and drive growth - Drug pricing reform (IRA) and other policy changes may shift biopharma pipeline focus over the next few years (i.e., potential move away from small molecules) . Our focus on biologics and the complexity of our work is uniquely tailored to this trend ■ China likely to become less favorable to U.S./Western clients due to continued geopolitical tension, reinforcing importance of US/EU-based CROS/CDMOS 35 FDA novel drug approvals in 2023 (through August); Tracking to surpass 2022 levels ~$50B YTD August 2023 annualized biotech funding; Tracking to be similar to 2018-19 levels Charles River Laboratories (CRL) 16

View entire presentation